Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer

Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer Full article

Journal

Mendeleev Communications
ISSN: 1364-551X , E-ISSN: 0959-9436

Output data

Year: 2012, Volume: 22, Number: 6, Pages: 287-289 Pages count : 3 DOI: 10.1016/j.mencom.2012.11.001

Authors

Rakitina Tatiana V. ^1,2,3 , Zeifman Alexey A. ^4,5 , Titov Ilya Yu. ^4,5 , Svitanko Igor V. ⁵ , Lipkin Aleksey V. ^2,3,6 , Stroylov Viktor S. ^4,5 , Stroganov Oleg V. ^4,5 , Novikov Fedor N. ^4,5 , Chilov Ghermes G. ^4,5

Affiliations

1	M. M. Shemyakin –Yu. A. Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russian Federation
2	Russian Research Center Kurchatov Institute, 123182 Moscow, Russian Federation
3	Moscow Institute of Physics and Technology (State University), 141700 Dolgoprudny, Moscow Region, Russian Federation
4	MolTech Ltd., 119992 Moscow, Russian Federation
5	N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, 119991,Moscow, Russian Federation
6	A. N. Bach Institute of Biochemistry, Russian Academy of Sciences, 119071 Moscow, Russian Federation

Novel rationally-designed Syk-kinase inhibitor MT-SYK-03 demonstrated equal potency with R406 (active metabolite of Fostamatinib, a phase III clinical trial candidate) in cellular models of autoimmunity and cancer with EC50 values in sub-micromolar range, while MT-SYK-322 was less active.

Rakitina T.V. , Zeifman A.A. , Titov I.Y. , Svitanko I.V. , Lipkin A.V. , Stroylov V.S. , Stroganov O.V. , Novikov F.N. , Chilov G.G.
Efficacy of Novel Syk-Kinase Inhibitors MT-SYK-03 and MT-SYK-322 in Cellular Models of Autoimmunity and Cancer
Mendeleev Communications. 2012. V.22. N6. P.287-289. DOI: 10.1016/j.mencom.2012.11.001 WOS Scopus OpenAlex

Web of science:	WOS:000312919100001
Scopus:	2-s2.0-84870356260
OpenAlex:	W2027384673

DB	Citing
OpenAlex	3
Scopus	3
Web of science	3